SEC Form 4 · accession 0001437749-17-005021
Sun BioPharma, Inc. · SNBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David B Kaysen
Officer — President and CEO · Director
Period of report
Mar 17, 2017
Accepted (ET)
Mar 21, 2017 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001029125
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $1.51 | Mar 17, 2017 | A | 248,000 | A | — | Dec 12, 2026 | Common Stock | 248,000 | 424,000 | D |
Explanation of responses
- F1On December 12, 2016, the reporting person was granted an option to purchase up to 800,000 shares of common stock. The option became exercisable with respect to 176,000 shares as of December 12, 2016 and with respect to an additional 248,000 shares as of March 17, 2017. The remainder is subject to vesting proportionately based on cash proceeds received by, or contractually obligated to be remitted to, the issuer after June 1, 2016 and before December 31, 2018 from any transaction, excluding certain internal operating-related cash flows.
- F2Option vested with respect to 248,000 additional shares pursuant to certification by issuer compensation committee.